

Appendix VI

EXTRAORDINARY INFORMATION DISCLOSURE

(Issued with the Decision No. 21/QĐ-SGDVN on December 21, 2021 of the CEO of Vietnam Exchange on the Information Disclosure Regulation of Vietnam Exchange)

**AGIMEXPHARM PHARMACEUTICAL
JOINT STOCK COMPANY**

**THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness**

No.: 06/CBTT-AGP

Long Xuyen City, March 08, 2025

EXTRAORDINARY INFORMATION DISCLOSURE

To: Hanoi Stock Exchange


1. Name of organization: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
- Stock code: AGP
- Address: No. 27 Nguyen Thai Hoc Street, My Binh Ward, Long Xuyen City, An Giang Province
- Tel: 02963.856964
- E-mail: agp@agimexpharm.com
2. Contents of disclosure: Resolution and Minutes of the 2025 Annual General Meeting of Shareholders.
3. This information was published on the company's website on March 08, 2025, as in the link <https://agimexpharm.com/shareholder/>

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.

Attached documents:

- Resolution and Minutes of the 2025 Annual General Meeting of Shareholders.
- Attached documents of the 2025 Annual General Meeting of Shareholders

**Legal representative
General Director**



Phar. Nguyen Van Kha

RESOLUTION

The 2025 Annual General Meeting of Shareholders

GENERAL MEETING OF SHAREHOLDERS

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021;

Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company;

Pursuant to the voting results on matters approved at the 2025 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company, held at Hoa Binh 1 Restaurant on March 8, 2025.

RESOLVED:

Article 1. Approval of the 2024 Board of Directors' activity report and assessment - Plans and targets for 2025; *Voting rate: 100%*.

Article 2. Approval of the 2024 Audited Financial Statements; *Voting rate: 100%*.

Article 3. Approval of the 2024 Board of Supervisors' report; *Voting rate: 100%*.

Article 4. Approval of the 2024 Board of Management's business operations report and plans for 2025; *Voting rate: 100%*.

Article 5. Approval of the proposals presented by the Board of Directors:

- 1) Proposal for selecting an auditing firm for the 2025 financial statements; *Voting rate: 100%*.
- 2) Proposal for the 2024 profit distribution and dividend payout; *Voting rate: 100%*.
- 3) Proposal for salary and bonus for the Board of Directors and the Board of Supervisors; *Voting rate: 100%*.
- 4) Proposal on the plan for issuing shares to pay 2024 dividends; *Voting rate: 100%*.
- 5) Proposal on the plan for issuing shares under the Employee Stock Ownership Program (ESOP); *Voting rate: 67.49% approval, 32.51% disapproval.*
- 6) Proposal on amendments to the Company's Charter; *Voting rate: 100%*.

Article 6. This resolution has been approved with a *voting rate of 100%* and shall take effect from the date of conclusion of the General Meeting. All shareholders of Agimexpharm Pharmaceutical Joint Stock Company, members of the Board of Directors, members of the Board of Supervisors, and all employees of the company are responsible for implementing this resolution. At the same time, the General Meeting of Shareholders authorizes the Board of Directors to detail this resolution into plans and tasks for directing and organizing its implementation.

Recipients:

- The Company's shareholders;
- The State Securities Commission;
- The Stock Exchange;
- Board of Directors;
- Board of Supervisors;
- Archived: Secretary of the BoDs.

**ON BEHALF OF THE PRESIDUM
CHAIRWOMAN OF THE BODS**



PHAR. PHAM THI BICH THUY

MINUTES

THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

Company name : AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
Headquarters : No. 27 Nguyen Thai Hoc St., My Binh Ward, Long Xuyen City, An Giang Province
Telephone : 0296 3856 960 **Fax:** 0296 3857 301
Website : www.agimexpharm.com
Business Registration Certificate : No. 1600699279 issued by the Department of Planning and Investment of An Giang Province on June 3, 2004, with subsequent amendments as of the latest change registration (18th time) on May 22, 2024
Start time : 8:30 AM on March 8, 2025
Venue : Hoa Binh 1 Restaurant
(130 Tran Hung Dao, My Binh Ward, Long Xuyen City, An Giang Province)

I. PARTICIPANTS, LEGALITY AND VALIDITY OF THE GENERAL MEETING

1. Participants

- Ms. Tran Thi Dao : Member of the Board of Directors
- Mr. Nguyen Quoc Dinh : Member of the Board of Directors
- Mr. Pham Uyen Nguyen : Member of the Board of Directors
- Ms. Tran Thi Thanh Hang : Head of the Board of Supervisors
- Mr. Nguyen Huu Danh : Director of A&C Auditing & Consulting Co., Ltd. Branch
- Ms. Pham Thi Bich Thuy : Chairwoman of the Board of Directors – Deputy General Director of Agimexpharm Pharmaceutical JSC
- Mr. Nguyen Van Kha : Vice Chairman of the Board of Directors – General Director of Agimexpharm Pharmaceutical JSC
- Mr. Huynh Hoang Ha : Member of the Board of Directors - Deputy General Director of Agimexpharm Pharmaceutical JSC
- Mr. Vu Minh Tuan : Deputy General Director of Agimexpharm Pharmaceutical JSC
- Esteemed Shareholders of the Company.

2. Legality and validity

Pursuant to the Shareholder Eligibility Verification Report dated March 8, 2025, prepared by the Shareholder Eligibility Verification Committee and presented by Ms. Tran Thi Thanh Hang on behalf of the Vote Checking Committee:

No.	Content	Number of Shareholders	Number of Shares	Percentage (%)
1	Total number of shareholders be invited and eligible to attend the General Meeting according to the list of shareholders as of February 10, 2025	775	23,143,941	100.00%
2	Number of absent shareholders who did not authorize voting rights	259	678,667	2.93%
3	Number of shareholders and authorized representatives attending the General Meeting	516	22,465,274	97.07%

Pursuant to Clause 1, Article 141 of the Enterprises Law and Clause 1, Article 18 of the Charter of Agimexpharm Pharmaceutical Joint Stock Company, the percentage of 97.07% of the voting shares is sufficient to proceed the General Meeting.

II. GENERAL MEETING CONTENT

- Ms. Nguyen Thi An, on behalf of the Organizing Committee, presented the Agenda, Working Regulations and Voting Procedures for the 2025 Annual General Meeting of Shareholders; introduced and conducted the voting to approve the Presidium, Secretariat and Vote Checking Committee with 100% approval:

The Presidium:

- Ms. Pham Thi Bich Thuy : Chairwoman of the Board of Directors - Deputy General Director
- Mr. Nguyen Van Kha : Vice Chairman of the Board of Directors – General Director
- Mr. Nguyen Quoc Dinh : Member of the Board of Directors
- Mr. Pham Uyen Nguyen : Member of the Board of Directors
- Mr. Huynh Hoang Ha : Member of the Board of Directors - Deputy General Director

The Secretariat:

- Ms. Le Ngoc Tran : Head of the Committee
- Ms. Le Minh Ngoc : Member

The Vote Checking Committee:

- Mr. Doan Thanh Nhan : Head of the Committee
- Mr. Nguyen Phuoc Duy : Member

- Ms. Pham Thi Bich Thuy presented the 2024 Board of Directors' activity report and assessment as well as plans and targets for 2025.
- Ms. Tran Nguyen Minh Hien presented the 2024 Financial Analysis Report.
- Mr. Nguyen Huu Danh presented the 2024 Independent Auditor's Report.
- Ms. Tran Thi Thanh Hang presented the 2024 Board of Supervisors' report and Proposal for selecting an auditing firm for the 2025 financial statements.
- Mr. Nguyen Van Kha presented the 2024 Board of Management's business operations report and plans for 2025.
- Mr. Huynh Hoang Ha presented the Proposal for the 2024 profit distribution and dividend payout; Proposal for salary and bonus for the Board of Directors and the Board of Supervisors; Proposal on amendments to the Company's Charter.

8. Mr. Pham Uyen Nguyen presented Proposal on the plan for issuing shares to pay 2024 dividends, Proposal on the plan for issuing shares under the Employee Stock Ownership Program (ESOP), and shared some side opinions.
9. The opinions shared by Ms. Tran Thi Dao and Mr. Nguyen Quoc Dinh – representative of IMEXPHARM’s capital contribution at AGIMEXPHARM.

- Attached documents.

III. CONCLUSION OF THE GENERAL MEETING

1. **Voting results:** The percentage of shareholders attending the General Meeting who voted:

No.	Content	Approve (%)	Disapprove (%)	No opinion (%)
1	The 2024 Board of Directors’ activity report and assessment - Plans and targets for 2025	100%	0%	0%
2	The 2024 Board of Management’s business operations report and plans for 2025	100%	0%	0%
3	The 2024 Audited Financial Statements	100%	0%	0%
4	The 2024 Board of Supervisors’ report	100%	0%	0%
5	Proposal for selecting an auditing firm for the 2025 financial statements	100%	0%	0%
6	Proposal for the 2024 profit distribution and dividend payout	100%	0%	0%
7	Proposal for salary and bonus for the Board of Directors and the Board of Supervisors	100%	0%	0%
8	Proposal on the plan for issuing shares to pay 2024 dividends	100%	0%	0%
9	Proposal on the plan for issuing shares under the Employee Stock Ownership Program (ESOP)	67.49%	32.51%	0%
10	Proposal on amendments to the Company's Charter	100%	0%	0%

2. Ms. Le Ngoc Tran presented the General Meeting Resolution which was approved with a voting rate of 100%.

3. The 2025 Annual General Meeting of Shareholders ended at 12:00 PM on the same day.

The Minutes of the 2025 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC. were prepared in 04 (four) copies and were duly approved at the Meeting.

ON BEHALF OF THE SECRETARY



LE NGOC TRAN

ON BEHALF OF THE PRESIDIUM

CHAIRWOMAN OF THE BOARD OF DIRECTORS



PHAM. PHAM THI BICH THUY

An Giang, February 14, 2025

**THE BOARD OF DIRECTORS' ACTIVITY REPORT,
ASSESSMENT OF THE COMPANY'S PERFORMANCE IN 2024
PLAN FOR 2025**

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC.

The Board of Directors ("BOD") of Agimexpharm Pharmaceutical Joint Stock Company respectfully presents to the Annual General Meeting of Shareholders ("GMS") the 2024 performance of the BOD and objectives for 2025, with the following key points:

I. ACTIVITIES OF THE BOARD OF DIRECTORS IN 2024

1. Activities of members of the Board of Directors

All members of the Board of Directors (BOD) exhibited a high level of responsibility, fully participating in meetings and effectively performing their functions of directing, managing, and supervising as required. The BOD reached strong consensus when approving resolutions and meeting minutes to promptly resolve challenges and obstacles arising in business operations. During meetings, the BOD forecasted the economic, political, and social situation, analyzed challenges, opportunities, and advantages, and formulated strategic directions for the company's development.

The BOD worked within its functions, duties and authority in compliance with the Enterprises Law, the company's charter and applicable laws. The BOD closely supervised the Board of Management's implementation of resolutions of the GMS and the BOD regarding key company matters.

The information disclosure policy complies with the regulations issued by the BOD according to the principles: Information is transparent, complete, accurate, standard and published on time.

Transactions between the company and its related parties, or between the company and major shareholders, insiders, and individuals related to insiders, were carried out in compliance with regulations (refer to section 2, part VII of the 2024 corporate governance report, which has been disclosed according to regulations).

Transactions between the Company and its affiliated persons or between the Company and its major shareholders, internal persons and affiliated persons (*refer to section 2, part VII of the 2024 Report on corporate governance, which has been disclosed according to regulations*).

2. Leadership and Supervision activities of the Board of Directors

In accordance with the Company's Charter and Corporate Governance Regulations, the BOD supervised and monitored the activities of the Board of Management in managing business operations and implementing the resolutions of the GMS and the BOD as follows:

Supervision methods:

- Receiving reports and directly questioning the Board of Management during regular BOD meetings.
- Monitoring the fulfillment of key targets committed by the Board of Management in accordance with the resolutions of the GMS and the BOD.
- Regular discussions among members to reach consensus on solutions regarding investment, finance, business operations, project management and procedures. Overseeing and directing the company's investment projects to ensure effective implementation.

Ongoing supervision allows timely decision-making and strategic direction to resolve difficulties and inadequacies in business operations.

- Risk management: Assessing and governing potential risks, including financial, human resources, legal, market and corporate governance risks.

Supervision results:

- The Board of Management and management team have implemented the resolutions and decisions of the GMS and the BOD.
- Throughout operations, the General Director and members of the Board of Management have complied with the regulations of the Company's Charter and Internal Governance Regulations.
- The General Director has fulfilled the role and responsibilities of a leader, directing and guiding critical company matters while efficiently coordinating the Board of Management's activities.
- Especially in 2024, despite a complex operating environment, the General Director managed production and business activities flexibly, proposed many timely solutions, adapted to the fluctuating business environment and completed the task of bringing practical value to shareholders.

***Conclusion:** The BOD considers 2024 a successful year for the company, reinforcing faith among shareholders, partners, and the entire Agimexpharm team.*

II. THE COMPANY'S PERFORMANCE EVALUATION IN 2024

1. Performance evaluation

2024 continues to be a volatile year for the global economy. The Vietnamese pharmaceutical industry faced numerous challenges and difficulties, including supply chain disruptions, rising production costs, intense competition and exchange rate pressures....

Faced with that common context, with the efforts and initiative of the Board of Directors and staff, Agimexpharm has implemented many solutions, taken advantage of opportunities, and overcome challenges to complete the targets set by the GMS.

The company strictly complied with the policies and regulations of the State, actively contributed to environmental protection, and fulfilled its social responsibilities.

Under the strategic direction of the BOD and in response to market difficulties, the Board of Management took decisive actions, proposed many flexible strategies, and implemented specific and creative solutions to complete the 2024 production and business plan.

Assessment of the implementation of the GMS' Resolutions:

CONTENT	IMPLEMENTATION RESULTS
1. The 2024 production and business targets	
Total revenue	VND 799.15 billion
Net revenue	VND 793.26 billion
Profit before tax	VND 60.48 billion
Profit after tax	VND 48.89 billion
2. Selection of independent auditing firm for the 2024 fiscal year	
Authorize the BOD to select 1 of 5 independent auditing firms	Choose A&C Auditing and Consulting Co., Ltd.
3. Profit distribution and dividend payment for 2023	
Dividend payment in shares at 12% of charter capital	The company issued 2,479,488 shares for the 2023 dividend

Bonus for the BOD and the Board of Supervisors for exceeding the profit plan by 1.27% of Profit After Tax	Bonus for the BOD and Board of Supervisors: VND 551,745,246
Allocation to the reward and welfare fund: 6.88% of Profit After Tax	Reward and welfare fund for 2023: VND 2,999,226,098
4. Addition of new business line	Added new business line: Warehousing and storage of goods
5. 2024 Salary and Bonus for the BOD, the Board of Supervisors, and the Board of Management	<i>Refer to item 1a, Section 1, part VII of the Notes to the Financial Statements – The Audited 2024 Financial Statements, which has been disclosed in accordance with regulations</i>

2. Key achievements

Despite capital difficulties due to the investment in the Betalactam Factory, 2024 revenue increased by 9%, and profit increased by 12% compared to the same period last year.

Product quality remains the core value, so the company consistently emphasizes quality management to ensure consumer health and high treatment efficacy.

The 2024 production output: 1.3 billion units, increased by 14% compared to 2023.

Research and development and product registration are invested: In 2024, the Department of Drug Administration granted 54 new registration numbers and 269 renewal numbers.

The Betalactam Factory project was completed with an area of 7,776 m². In early December 2024, the Department of Drug Administration confirmed its GMP compliance.

In 2024, Agimexpharm achieved several achievements: “Vietnamese Drug Star Award – 2nd Edition”, Top 10 ASEAN Strong Brands, Top 100 Vietnam's National Brand – Vietnam Gold Star Award 2024, Vietnam High Quality Goods, Outstanding Enterprise for Employees, and Cultural Enterprise.

The company developed policies for employee benefits, salary, bonus, and training programs to enhance professional skills and ensuring long-term employee loyalty.

As a responsible manufacturer, Agimexpharm focuses on investing in health and safety standards for employees, minimizing environmental impact, and meeting waste treatment standards. The company also increased green coverage at operational sites, engaged in traditional community activities, and contributed to charity funds, scholarships and local government initiatives...

III. PLAN FOR 2025

1. Identifying Opportunities, Challenges, and Risks

The global economic and political situation in 2025 is expected to have a significant impact on the growth of pharmaceutical companies:

- U.S. Tariff Policies: Potential increases in import tariffs could affect the supply chain for pharmaceutical raw materials
- Political conflicts: These could lead to higher energy costs and put pressure on global economic stability, impacting production and distribution activities for pharmaceutical companies.
- Global economic growth: According to United Nations forecasts, global economic growth is expected to remain at 2.8% in 2025. Slower growth could affect consumer demand, including spending on pharmaceuticals

Based on the analysis above, Agimexpharm is facing numerous advantages, challenges, and growth opportunities:

- Regulatory adjustments and additions in the Pharmaceutical Law create a clear legal framework that supports the sustainable development of the company

- Response speed and adaptability are the most influential factors in the company's business results, especially in periods of significant volatility.
- R&D: Agimexpharm has a diverse product portfolio and the ability to effectively leverage its products.
- Technological innovation and process improvement: The management team is dynamic, willing to innovate and act.
- Financial strength: The company's capital is still insufficient to meet its working capital needs and medium-to-long-term investment requirements.
- Human resource quality: There is a shortage of skilled labor to elevate quality and prepare for future leadership succession.
- Sales system and distribution network have not yet been professionally invested in.

2. Target and Plan of the Board of Directors

2.1. Business Plan for 2025

Target	Actual 2024	Plan for 2025	Growth rate (%)
Net Revenue (VND billion)	793.3	868	9.4%
Profit Before Tax (VND billion)	60.5	68	12.4%
Profit Margin (Profit Before Tax/Revenue) (%)	7.6%	7.8%	

2.2. Corporate Governance Objectives

The Vietnamese pharmaceutical industry in 2025 presents numerous growth opportunities but also faces significant challenges. Leveraging advantages and opportunities while overcoming difficulties will be key to Agimexpharm's sustainable development in the future. The BOD has set the following main objectives:

- Ensure responsible governance and compliance with legal regulations, the Company's Charter and the BODs' operational regulations.
- Coordinate with the Board of Supervisors to fully understand the company's operations and provide valuable advice and recommendations to support the Board of Management.
- Strengthen supervision, evaluation and feedback on the Board of Management's activities regarding investments, finance, business operations, production, quality risk management, human resources, project management, etc. Solutions need to be developed to increase the company's capital.
- Organize BOD meetings to promptly address issues with the Board of Management, overcoming obstacles and creating favorable conditions for all company activities.
- Coordinate with the Board of Management in relationships with shareholders, investors, partners, employees and other stakeholders.

Above is the Board of Directors' Activity Report, Evaluation of the Company's Performance in 2024 and outlining plan for 2025. On behalf of the Board of Directors, we would like to sincerely thank our shareholders, investors, partners, customers, and all employees for their trust and support during the past period and in the future.

Sincerely,

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRWOMAN



PHẠM THỊ BÍCH THUY

An Giang, February 14, 2025

AUDITED FINANCIAL STATEMENTS
YEAR 2024

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC.

The 2024 audited financial statements of Agimexpharm Pharmaceutical Joint Stock Company have been audited by A&C Auditing and Consulting Co., Ltd. and disclosed in accordance with regulations and published on the company's website, including:

1. Statement of the Board of Directors
2. Independent auditor's report
3. Balance sheet
4. Income statement
5. Cash flow statement
6. Notes to the financial statements

Among them, some key figures from the 2024 audited financial statements are as follows:

Unit: Vietnamese Dong (VND)

STT	Key indicators	2024	2023
1	Total assets	1,094,278,885,505	897,763,414,064
2	Gross revenue	799,149,067,144	728,406,444,724
3	Net revenue	793,261,193,442	725,130,106,273
4	Profit before tax	60,481,183,498	54,195,754,105
5	Profit after tax	48,889,738,710	43,612,786,683

Respectfully submitting to the General Meeting of Shareholders for consideration and approval.

Sincerely!

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRWOMAN

CÔNG TY
CP
DUỐC PHẨM
AGIMEXPHARM
T.P. LONG XUYÊN, T. AN GIANG

PHẠM PHAM THI BICH THUY

A&C AUDITING AND CONSULTING CO., LTD.

Head Office : 02 Truong Son St., Tan Binh Dist., Ho Chi Minh City, Vietnam
Branch in Ha Noi : 40 Giang Vo St., Dong Da Dist., Ha Noi City, Vietnam
Branch in Nha Trang : Lot STH 06A.01, Sl. No.13, Le Hong Phong II Urban Area, Nha Trang City, Vietnam
Branch in Can Tho : 15-13 Vo Nguyen Giap St., Cai Rang Dist., Can Tho City, Vietnam

Tel: +84 (028) 3547 2972 kttv@a-c.com.vn
Tel: +84 (024) 3736 7879 kttv.hn@a-c.com.vn
Tel: +84 (0258) 246 5151 kttv.nt@a-c.com.vn
Tel: +84 (0292) 376 4995 kttv.ct@a-c.com.vn



www.a-c.com.vn

No. 4.0029/25/TC-AC

INDEPENDENT AUDITOR'S REPORT

To: THE SHAREHOLDERS, THE BOARD OF MANAGEMENT AND THE BOARD OF DIRECTORS
AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

We have audited the accompanying Financial Statements of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company"), which were prepared on 12 February 2025 (from page 06 to page 42), including the Balance Sheet as of 31 December 2024, the Income Statement, the Cash Flow Statement for the fiscal year then ended and the Notes to the Financial Statements.

Responsibility of the Board of Directors

The Company's Board of Directors is responsible for the preparation, true and fair presentation of these Financial Statements in accordance with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and relevant statutory requirements on the preparation and presentation of Financial Statements; and responsible for such internal control as the Company's Board of Directors determines necessary to enable the preparation and presentation of the Financial Statements to be free from material misstatement due to frauds or errors.

Responsibilities of Auditors

Our responsibility is to express an opinion on these Financial Statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with ethical standards and requirements and plan and perform the audit to obtain reasonable assurance about whether the Financial Statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Financial Statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Financial Statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and true and fair presentation of the Financial Statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Company's Board of Directors, as well as evaluating the overall presentation of the Financial Statements.

We believe that the audit evidences we have obtained are sufficient and appropriate to provide a basis for our audit opinion.

Opinion of the Auditors

In our opinion, the Financial Statements give a true and fair view, in all material respects, of the financial position as of 31 December 2024 of Agimexpharm Pharmaceutical Joint Stock Company, its financial performance and its cash flows for the fiscal year then ended, in conformity with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and relevant statutory requirements on the preparation and presentation of Financial Statements.

For and on behalf of
A&C Auditing and Consulting Co., Ltd.
Can Tho Branch



Nguyễn Hữu Danh
Partner

Audit Practice Registration Certificate No.1242-2023-008-1
Authorized Signatory

Can Tho City, 12 February 2025

Nguyễn Thuy Trang
Auditor

Audit Practice Registration Certificate No.3592-2021-008-1

REPORT OF THE BOARD OF SUPERVISORS 2024

The Board of Supervisors of Agimexpharm Pharmaceutical Joint Stock Company (AGP) hereby reports on its activities in 2024 as follows:

I/ ACTIVITIES OF THE BOARD OF SUPERVISORS:

In 2024, the Board of Supervisors carried out its duties in accordance with its Working Regulations and the 2024 Work Program while ensuring compliance with the Enterprise Law. Representatives of the Board of Supervisors participated in the company's periodic inventories and attended meetings of the Board of Directors.

II/ ASSESSMENT OF BUSINESS PERFORMANCE:

1- REVIEW OF BUSINESS PERFORMANCE REPORT:

1.1- General assessment of business performance in 2024:

(Unit: Million VND)

No.	Business performance results	Y2020	Y2021	Y2022	Y2023	Y2024	Y2024/Y2023	
1	Revenue	515,861	533,994	700,795	728,406	799,149	70,743	10%
2	Revenue deductions	20,882	12,195	13,747	3,276	5,888	2,612	80%
3	Net revenue	494,978	521,799	687,047	725,130	793,261	68,131	9%
4	Cost of sales	332,373	334,800	457,696	510,404	560,244	49,840	10%
5	Gross profit	162,606	186,998	229,351	214,726	233,017	18,291	9%
6	Financial income	762	693	1,129	631	2,975	2,344	372%
7	Financial expenses	19,617	21,395	28,616	39,090	32,598	(6,492)	-17%
-	In which: Loan interest expenses	17,229	18,424	24,161	35,448	29,377	(6,071)	-17%
9	Selling expenses	81,447	95,356	108,172	82,645	97,704	15,059	18%
10	General and administration expenses	26,149	29,918	40,747	39,693	45,095	5,402	14%
11	Net profit/loss	36,155	41,023	52,946	53,929	60,595	6,666	12%
12	Other income	150	355	342	266	183	(84)	-31%
13	Other expenses	7	-	48	-	297	297	
14	Other profit	143	355	294	266	(114)	(380)	-143%
15	Profit before tax	36,298	41,378	53,239	54,196	60,481	6,285	12%
16	Income tax	7,427	8,151	10,329	10,583	11,591	1,008	10%
18	Profit after tax	28,870	33,226	42,910	43,613	48,890	5,277	12%

Observations:

- Net revenue increased by 9%, demonstrating AGP's strong growth momentum and increasing market share. However, deductions also saw a significant rise.
- Cost of sales increased by 10%, higher than net revenue. Compared to 2023, cost of sales was better managed, allowing gross profit to maintain a 9% increase.
- Financial income rose significantly, while loan interest expenses dropped sharply, marking a key highlight of 2024 that contributed to additional profits.
- Selling expenses increased significantly: Gross profit rose by VND 18 billion, selling expenses increased by VND 15 billion. General and administrative expenses also rose by more than VND 5 billion.

- Other income, expenses and profits remained stable.

General assessment: Most expenses increased, except for financial expenses, which decreased by over VND 6 billion, leading to a corresponding increase in net profit by VND 6 billion. In 2024, while net revenue increased by VND 68 billion, cost of sales increased by VND 50 billion, selling expenses increased by VND 15 billion, and general and administrative expenses increased by VND 5 billion (approximately VND 70 billion in total). Therefore, this year's company profit increased mainly thanks to the reduction of financial expenses. Net revenue reached 103%, and profit before tax achieved 104% of the annual target.

1.2- Detailed revenue and expenses:


I. REVENUE	Y2020	Y2021	Y2022	Y2023	Y2024	Y2024/Y2023		
1 Net revenue	494,978	521,799	687,047	725,130	793,261	68,131	9%	
2 Financial income	762	693	1,129	631	2,975	2,344	372%	
3 Other income	150	355	342	266	183	(84)	-31%	
Total Revenue	495,890	522,847	688,518	726,027	796,418	70,391	10%	
II. EXPENSES								
1 Cost of sales	332,373	334,800	457,696	510,404	560,244	49,840	10%	
2 Financial expenses	19,617	21,395	28,616	39,090	32,598	(6,492)	-17%	
3 Selling expenses	81,447	95,356	108,172	82,645	97,704	15,059	18%	
4 General and administration expenses	26,149	29,918	40,747	39,693	45,095	5,402	14%	
5 Other expenses	7	-	48	-	297	297		
6 Income tax	7,427	8,151	10,329	10,583	11,591	1,008	10%	
Total expenses	467,020	489,620	645,608	682,414	747,529	65,114	10%	
Total expenses/Total revenue ratio	94.2%	93.6%	93.8%	94.0%	93.9%	-0.13%	0%	

Observations:

- Revenue: Both total revenue and financial income increased. Other incomes decreased slightly. Total revenue increased by more than VND 70 billion.
 - Expenses: Cost of sales, selling expenses, and general and administrative expenses all increased by more than 10%, higher than the revenue growth. Financial expenses decreased by 17%.
- Total expenses/revenue ratio: 93.9%, showing a slight decrease but still maintaining a level like previous years, without significant improvement.

III. Proportion of total revenue	Y2020	Y2021	Y2022	Y2023	Y2024	Y2024/Y2023		
1 Cost of sales	67.0%	64.0%	66.5%	70.3%	70.3%	0.04%	0.1%	
2 Financial expenses	4.0%	4.1%	4.2%	5.4%	4.1%	-1.29%	-24.0%	
3 Selling expenses	16.4%	18.2%	15.7%	11.4%	12.3%	0.88%	7.8%	
4 General and administration expenses	5.3%	5.7%	5.9%	5.5%	5.7%	0.20%	3.6%	
5 Other expenses	0.0%	0.0%	0.0%	0.0%	0.0%	0.04%		
6 Income tax	1.5%	1.6%	1.5%	1.5%	1.5%	0.00%	-0.2%	
7 Profit after tax	5.8%	6.4%	6.2%	6.0%	6.1%	0.13%	2.2%	

- Cost of sales ratio: The highest at 70.3%, which has not decreased.
- Financial expenses ratio: A significant reduction in 2024.
- Selling expenses ratio: The second highest at 12.3%, increased compared to 2023.
- General and administrative expenses ratio: A slight increase.
- Net profit ratio: Increased by 0.13%, which is negligible.



2- FINANCIAL STATEMENTS CONTROL (As of December 31, 2024)

B/	BALANCE SHEET	Y2020	Y2021	Y2022	Y2023	Y2024	Y2024/Y2023	Proportion	
**	BALANCE SHEET	420,463	498,683	528,116	579,184	609,779	30,594	5%	56%
	Cash and cash equivalents	14,869	24,177	8,884	28,594	13,948	(14,646)	-51%	1%
	Short-term financial investments	3,019	-	959	6,098	6,098	-	0%	1%
	Short-term receivables	197,475	202,096	231,730	239,342	258,783	19,441	8%	24%
	Inventories	196,323	258,984	272,282	290,486	308,381	17,896	6%	28%
	Other current assets	8,777	13,426	14,261	14,665	22,568	7,903	54%	2%
**	NON-CURRENT ASSETS	178,748	172,187	274,324	318,579	484,500	165,921	52%	44%
	Long-term receivables	11,743	5,104	8,342	9,210	4,954	(4,255)	-46%	0%
	Fixed assets	136,743	131,358	208,939	242,845	409,569	166,724	69%	37%
	Long-term assets in process	8,572	20,259	32,049	44,025	47,428	3,402	8%	4%
	Long-term financial investments	10,310	12,587	22,269	17,131	17,131	-	0%	2%
	Other non-current assets	11,380	2,878	2,725	5,368	5,418	50	1%	0%
	TOTAL ASSETS	599,211	670,870	802,440	897,763	1,094,279	196,515	22%	100%
**	LIABILITIES	381,442	438,640	488,272	543,079	694,419	151,340	28%	63%
	Current liabilities	363,738	415,893	456,231	525,294	575,850	50,557	10%	53%
	Non-current liabilities	17,705	22,747	32,041	17,786	118,569	100,784	567%	11%
**	OWNER'S EQUITY	217,769	232,230	314,168	354,684	399,859	45,175	13%	37%
	Owner's equity	217,769	232,230	314,168	354,684	399,859	45,175	13%	37%
	TOTAL LIABILITIES AND OWNER'S EQUITY	599,211	670,870	802,440	897,763	1,094,279	196,515	22%	100%

Observations:

- The two high-weight items are being well managed, including: short-term receivables increased by 8%, and inventories increased by 6%.
- Long-term assets increased by 52%, with the company's fixed assets accounting for over 37% starting in 2024, a significant increase compared to previous years. Fixed assets have become the highest proportion of total assets, contributing to a 22% increase in AGP's total assets.

- Liabilities and equity of the company both increased significantly, with liabilities rising faster, resulting in an increase in the Liabilities/Total liabilities and owner's equity ratio compared to 2023, while the Equity/Total liabilities and owner's equity ratio decreased to 37%.

Overall, the company's total liabilities and owner's equity increased by VND 196.5 billion, stemming from a VND 150 billion increase in borrowings and the company's profit in 2024.

Financial indicators:

C/	FINANCIAL RATIOS	Y2020	Y2021	Y2022	Y2023	Y2024	Y2024/Y2023	
**	Capital efficiency and profitability							
	ROE (Profit after tax/Owner's equity)	13.3%	14.3%	13.7%	12.3%	12.2%	-0.1%	-1%
	ROA (Profit after tax/Total assets)	4.8%	5.0%	5.3%	4.9%	4.5%	-0.4%	-8%
	ROS (Profit after tax /Net revenue)	5.8%	6.4%	6.2%	6.0%	6.2%	0.1%	2%
	Gross profit /Net revenue	32.9%	35.8%	33.4%	29.6%	29.4%	-0.2%	-1%
**	Capital structure, financial stability							
	Liabilities/Owner's equity	175%	189%	155%	153%	174%	20.5%	13%
	Liabilities/Total assets	64%	65%	61%	60%	63%	3.0%	5%
**	Growth indicators							
	Revenue growth rate (times)	1.1	1.1	1.3	1.1	1.1	3.9%	4%
	Profit growth rate (times)	1.0	1.2	1.3	1.0	1.1	10.5%	10%

- ROE and ROA of AGP both decreased this year compared to the previous year due to an increase in owner's equity and total assets.
- ROS increased slightly, but gross profit/revenue this year was less effective compared to previous years.
- The company's liability structure improved in 2022 and 2023, but the liability ratio increased again in 2024.
- Công ty luôn duy trì tốt đà tăng trưởng DT & LN qua các năm.
- The company has maintained strong growth in revenue and profit over the years.

In recent years, despite facing numerous challenges and strong competitors in the market, the company has consistently maintained growth in revenue, profit, and working capital management. Although there are still risks due to liabilities being higher than equity, the effective use of leverage has enabled the company to dominate and maintain its market share in its field. While financial indicators have not improved significantly, the company could explore ways to enhance them to attract investment more effectively.

3- COMPLIANCE CONTROL:

- Books and accounting software are updated thoroughly and clearly, recording all data in accordance with company regulations and accounting standards. All payment documents are complete, legal, and reasonable.
- Accounts receivable, bank balances, loan amounts, and inventory data (raw materials, finished goods, etc.) are fully supervised in detail, with reconciliation and verification. The Internal Board of Supervisors regularly checks, sends reports, and collaborates with the Board of Supervisors for supervising.
- The 2024 financial statements have been prepared in the correct format in accordance with Vietnamese accounting standards and current regulations. The figures presented in the 2024 financial statements are complete, timely, clear, accurate, truthful, and reasonable; they have been independently audited.

4- SUPERVISING OF THE ACTIVITIES OF THE BOARD OF DIRECTORS AND THE BOARD OF MANAGEMENT:

- The Board of Directors and the Board of Management always comply with the Charter, Governance Regulations and resolutions of the Annual General Meeting of Shareholders. They fully implement the disclosure of information as required by law. In coordination with the Board of Supervisors, they carry out the inspection and supervision of business operations in accordance with the Enterprise Law, Charter, and resolutions of the General Meeting of Shareholders. The results show no violations have been detected.
- The Board of Supervisors agrees with all contents of the assessment of the Board of Directors' activities, as outlined in the Board of Directors' summary report on business operations for 2024 and plans for 2025.

III/ RECOMMENDATIONS:

The Board of Supervisors agrees with the Board of Directors' summary report on business operations for 2024. The company's operations have always complied with the company's Charter, the resolutions of the General Meeting of Shareholders, and legal regulations. The business operations in 2024 resulted in profit, with the Board of Directors and the Board of Management working effectively and consistently implementing correct, flexible, and market-appropriate strategies. The Board of Directors' meetings have set clear objectives and addressed issues promptly and thoroughly. Therefore, the Board of Supervisors recommends the following:

1. Focus on managing the two major cost items: Cost of sales and Selling expenses, while maintaining stability in other cost groups to prevent significant increases.
2. Reduce receivables to provide additional business capital for the company.

This is a summary of the supervisory process conducted by the Board of Supervisors and presented before the General Meeting of Shareholders. We sincerely hope to receive valuable feedback from esteemed shareholders to help us in fulfilling our responsibilities in the upcoming period.

Best regards.

**ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD**



MBA. TRAN THI THANH HANG

An Giang, February 14, 2025

**REPORT OF THE BOARD OF MANAGEMENT
ON BUSINESS OPERATIONS IN 2024
AND PLAN FOR 2025**

The year 2024 continues to mark an important milestone in Agimexpharm's journey towards sustainable growth and continuous advancement. Under the leadership of the Board of Directors and the Board of Management, along with the support of shareholders and the efforts of all employees, the Company has overcome numerous challenges to maintain stable growth and fulfill the responsibilities entrusted by our esteemed shareholders. The key achievements are as follows:

1. Revenue and Profit

- Revenue: VND 793.3 billion, rising by 9.4% compared to 2023, exceeding the target by 3%.
- Profit before tax: VND 60.5 billion, rising by 11.6%, exceeding the target by 4.3%.
- Profit after tax: VND 48.9 billion, rising by 12.1%, exceeding the target by 4.7%.

Unit: Million VND

Indicator/Year	2020	2021	2022	2023	2024	5-Year Average
Revenue	494,978	521,798	687,047	725,130	793,261	11.6%
Profit before tax	36,298	41,378	53,239	54,196	60,481	11.6%
Profit after tax	28,870	33,226	42,910	43,613	48,890	11.9%

The results above reflect the sustainable effectiveness of the company's business strategy, market expansion, and strict adherence to financial regulations.

2. Production and Distribution

- **Production:** The production output for the past year is as follows:

Unit: Million VND

Product	ĐVT	2020	2021	2022	2023	2024	+/-% 2023
Powder Sachets	Sachet	19.38	21.35	34.38	33.29	32.23	-3.2%
Suspension Sachets	Sachet	0.35	11.81	17.52	16.21	14.98	-7.6%
Capsules	Capsule	115.83	132.95	166.40	198.92	235.32	18.3%
Tablets	Tablet	601.16	690.07	827.72	923.78	1,051.48	13.8%
Liquid Medicine	Sachet/ Vial/ Bottle	14.32	2.14	4.13	3.70	6.37	72.2%
Granules	Bottle	0.51	0.35	0.50	0.49	0.41	-16.3%
Creams	Tube	0.84	0.73	0.74	1.05	1.30	23.8%
Total		752.39	859.42	1,051.39	1,177.44	1,342.09	14.0%

Agimexpharm has optimized production capacity at 4 factories, including: My Thoi Capsule-Granule-Powder; My Thoi Cream-Ointment-Liquid; Binh Hoa Non-Betalactam Capsule-Granule-Powder; Herbal medicine and Health supplement. As a result, the total production output reached 1.34 billion units, a 14% increase compared to the year 2023, along with the development of 30 new products and new packaging formats. This achievement was made possible by:

- The application of automation and management software has helped improve productivity and minimize errors.

- The testing laboratory compliant with GLP.ISO 13485 standards, equipped with advanced technology and a highly skilled team, completed **21,000 samples** during the year, ensuring product quality complies with the strict pharmaceutical industry regulations.
- Strengthened quality assurance (QA): regular inspections and audits to ensure products are manufactured according to quality procedures.

• **Distribution:**

Agimexpharm has a **diverse product portfolio** with **597 finished product codes** currently supplied to customers, which strengthens the company’s competitiveness in the challenging pharmaceutical environment. The market share and growth rates of the product groups are as follows:

Group	% of 2024 Revenue	% of 2023 Revenue
Anti-inflammatory agents, Antibiotics, Antivirals, Antihistamines	32.4%	32.7%
Cardiovascular system, Antidiabetic	21.2%	21.2%
Alimentary tract and Metabolism	14.3%	15.4%
Health supplements-Cosmetics-Medical devices; Vitamins-Minerals, Herbal medicines	9.5%	10.3%
Other groups (Analgesics, Skeletal Muscle Relaxants, Nervous system, Genitourinary system...)	22.6%	20.4%

The ETC channel played a key role and grew compared to the year 2023, accounting for **51%** of total revenue. The OTC channel declined at branch levels due to intense competition between traditional pharmacies and new chain systems. Meanwhile, the manufacturing facilities attracted more contract manufacturing partners, contributing to revenue and serving as an effective branding tool, reinforcing the company’s reputation and product quality.

Nationwide distribution: **An Giang Province** played a key role in maintaining stability (accounting for 34% of revenue, increasing by 7%). The key market of **Ho Chi Minh City and neighboring provinces** (accounting for 41% of revenue, increasing by 13%), while **Da Nang and the Central region** (accounting for 22%, increasing by 11%). Revenue from the **Northern region** serves as a foundation for future growth.

In addition to the domestic market, Agimexpharm is actively expanding into international markets. In 2024, the company made significant progress by maintaining exports to Cambodia and Myanmar, while also targeting new markets such as South Korea, Yemen, Somalia and Afghanistan.

To ensure the timely and accurate distribution of its products, Agimexpharm’s logistics and warehousing system operates with **31 personnel**, managing **5 warehouses** with a total area of **7,589m²**. The fleet includes **7 trucks** (ranging from 500 kg to 8 tons), which transported **9,694 tons** of raw materials and packaging and **4,150 tons** of finished products in 2024.

3. Innovation and Sustainable Development Investment

In 2024, new asset investments totaled **VND 195 billion**, allocated to the construction of the Betalactam Plant, maintenance and upgrades of existing assets, infrastructure expansion, the addition of 3 solar energy systems, production machinery, and testing equipment. This represents the highest investment level to date, raising the total value of fixed assets to **VND 562 billion, increasing by 53%**. Additionally, ongoing projects and equipment under construction amount to **VND 47 billion**, including the expanded Herbal Medicine Plant, the Liquid Pharmaceutical Plant (for infusions, injections, and eye drops), and the Canteen and Parking facility for the Binh Hoa Industrial Park manufacturing complex.

Continuous investment is a crucial step, reflecting the strategic vision of the Board of Management to be ready to meet the growing demands of the market and lay the foundation for future growth. The Betalactam Antibiotic Plant with an area of **7,776m²**, was completed after 14 months of construction and successfully passed the evaluation process. It is now capable of developing new product lines.

The R&D team has completed **750 registration files**, including product registrations, renewals, and various procedures, resulting in the issuance of **717 marketing authorizations**. They also conducted **410 research samples**, of which **111 samples** met the required quality standards.

In line with energy-saving initiatives and green production strategy, a new solar energy system was installed, adding **1,317 kW** in 2024. As a result, the company's total capacity reached **2,465 kW**, reducing electricity costs by **VND 7 billion** per year, cutting carbon emissions, and contributing to environmental protection.

4. People and Social responsibility

With a long-term vision, Agimexpharm has made sustainable investments in human resources, simultaneously fulfilling its social responsibilities and laying a solid foundation for long-term growth.

By the end of 2024, the company had nearly **490 employees** working in a well-structured environment with comprehensive welfare policies. Employees are empowered to develop their capabilities, provided with career advancement opportunities, and receive competitive salaries and benefits. The total salary expenditure for the year 2024 reached **VND 52.5 billion, rising by 7%**. The recognition and rewards for outstanding individuals and teams serve as motivation for continued growth.

For shareholders, Agimexpharm ensures the protection of interests and capital preservation by maintaining stable dividends and sustainable stock value. In 2024, the company distributed **dividends at 12%**. As of December 31, 2024, the stock price was **VND 38,900 per share**, reflecting stability and market confidence in the company's development strategy.

In fulfilling its responsibilities to the State, Agimexpharm remains highly aware of its obligations beyond business growth. In 2024, the company fully complied with tax obligations, contributing **VND 14 billion** to the national budget.

5. Awards and Certifications

Top 10 Asean Strong Brand

Top 100 Vietnam's National Brand – Vietnam Gold Star Award 2024

Vietnam High Quality Goods

Vietnam Pharmaceutical Star Award

2023-2024 Cultural Enterprise

Outstanding Enterprise for Employees

GMP, GSP, GLP, GDP Certifications; ISO 13485:2016

6. Challenges and Opportunities

The rising cost of raw materials remains a significant challenge, accounting for a substantial portion of product costs and being influenced by various factors such as transportation expenses, exchange rates, supply chain disruptions, and stringent regulations. Over the year, the company spent **VND 480 billion** on raw materials and packaging, including direct imports of **30 types** of materials with a total value of **VND 84 billion** (increased 1.75 times). Optimizing raw material costs, combined with efforts to diversify supply sources, helps Agimexpharm improve its competitiveness and proactively respond to future challenges related to raw material costs.

Capital is another significant challenge when expanding scale and investing in strategic projects. From the shareholders' contributed capital of **VND 231 billion**, assets have now grown to **VND 1,094 billion**. The equity turnover ratio reached **2.1 times**, and the return on equity (ROE) was **13%**, affirming profitability and long-term growth potential. As a result, the company has opportunities to access funding from banks for buying raw materials and implementing investment projects.

Effective cash flow management ensures liquidity. Cash flow from operating activities reached **VND 60.8 billion**, an increase compared to 2023, thanks to enhanced cost control, sales, and debt

collection. Cash flow from financing activities reached **VND 130 billion**, supported by bank funding. The Company's cash flow statement is presented in the following table:

Unit: Million VND

Cash flow	2020	2021	2022	2023	2024
Operating activities	(716)	14,999	25,500	50,250	60,755
Investment activities	(27,049)	(23,441)	(126,696)	(75,782)	(205,384)
Financing activities	22,237	17,752	85,889	45,234	129,988
Total	(5,527)	9,310	(15,307)	19,702	(14,641)

7. Plan for 2025

- Maintain a revenue growth rate of 10% or more, aiming to reach VND 1,000 billion within the next 3 years.

Target (Billion VND)	Actual 2024	Plan for 2025	Growth rate (%)
Revenue	793.3	868	9.4%
Profit before tax	60.5	68	12.4%

- Expand into new markets while strengthening current market.
- Continue implementing projects: Expansion of the Herbal Medicine Factory, Liquid Medicine Factory, Food Factory, Canteen and Parking Lot to meet coverage requirements at Binh Hoa Industrial Park.
- Exploiting the capacity of completed factories.
- Tighten cash flow management.
- Develop human resources, enhance professional skills and leadership capabilities, encourage innovation, optimize work processes and increase productivity.

8. Conclusion - "Keep Faith"


The outstanding achievements of 2024 and previous years reflect the sustainable development of Agimexpharm. We are fully confident in our direction and development plans thanks to:

- 1) An experienced and passionate workforce leading a dynamic and creative young team to form a high-quality labor force.
- 2) Continuously investing and upgrading machinery and equipment to keep up with advances in science and technology helps enhance productivity, product quality and automation.
- 3) The product list is continuously supplemented and improved to increase competitiveness and expand the market: add lines of Betalactam antibiotics, injections, infusions, and eye drops.
- 4) Shareholders and partners always stand by Agimexpharm and share long-term benefits together.

These factors form the foundation of Agimexpharm today and its growth potential in the future. On behalf of all Agimexpharm's Shareholders, Partners, Government Agencies, and Employees, we express our sincere gratitude and strive to bring worthy value while maintaining sustainable growth.

Sincerely thank you and best regards!

AGIMEXPHARM PHARMACEUTICAL JSC
GENERAL DIRECTOR



PHAR. NGUYEN VAN KHA

No.: 01/TT-AGP.DHDCD

An Giang, February 14, 2025

**PROPOSAL
SELECTION OF AN AUDIT FIRM
FOR THE 2025 FINANCIAL STATEMENTS**

To: The 2025 Annual General Meeting of Shareholders

- Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021.
- Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company.
- Pursuant to the Company's actual circumstances.

The Board of Supervisors proposes that the General Meeting of Shareholders authorizes the Board of Directors to select one (1) of the following five (5) Audit Firms for the 2025 financial statements:

- Deloitte Vietnam Co., Ltd.
- AASC Auditing Firm Co., Ltd.
- A&C Auditing and Consulting Co., Ltd.
- DFK Vietnam Auditing Co., Ltd.
- Sao Viet Auditing Co., Ltd.

Selection criteria:

- The audit firm must be approved by the State Securities Commission as eligible to conduct audits in 2025.
- The audit firm must be reputable and experienced.
- The service fee must be reasonable.

We respectfully submit this proposal to the General Meeting of Shareholders for approval and authorize the Board of Directors to select an audit firm for the 2025 financial statements audit.

We look forward to the approval of the Esteemed Shareholders.

Sincerely,

**ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD**



MBA. TRAN THI THANH HANG

PROPOSAL
FOR THE 2024 PROFIT DISTRIBUTION AND DIVIDEND PAYOUT
(For the fiscal year ending 31 December, 2024)

To: The 2025 Annual General Meeting of Shareholders

Pursuant to the business performance results of 2024 and the 2024 Audited Financial Statements dated February 12, 2025, the Board of Directors proposes the profit distribution and dividend payout for 2024 as follows:

Unit: VND (Vietnamese Dong)

Items	Percentage	Amount	Notes
Profit before tax		60,481,183,498	
Corporate income tax		11,591,444,788	
Retained earnings		48,889,738,710	
1/ Appropriation for bonus fund for the Board of Directors and the Board of Supervisors	1.49%	728,871,010	
2/ Appropriation for Bonus and Welfare Fund	7.50%	3,667,008,458	
3/ Dividend payout:	71.01%	34,715,911,500	15% of charter capital
3.1 In form of cash (5%)	23.67%	11,571,970,500	5% of charter capital
3.2 In form of shares (10%) (Details in the Proposal on Plan for issuing shares to pay dividends)	47.34%	23,143,941,000	10% of charter capital
4/ Remaining profit appropriate for Development and Investment Fund	20.00%	9,777,947,742	

Notes:

1/ Appropriation for the 2024 bonus fund for the Board of Directors and the Board of Supervisors as follows:

Total bonus fund for the Board of Directors: VND 728,871,010

Bonus for meeting the profit before tax plan (1% of profit before tax): VND 604,811,835

Bonus for exceeding the profit before tax plan (5% of excess profit): VND 124,059,175

2/ Bonus and Welfare Fund: Used for rewards, employee welfare, and other social welfare activities.

3/ Investment and development fund: Used for expanding business operations, purchasing fixed assets (land, machinery, equipment, transportation, vehicles), scientific research, product development research, training, offsetting tax settlement differences, and losses in assets and debts. The Board of Directors authorizes the Board of Management to review the use of this fund within the limits as prescribed by law or the company's charter.

Sincerely.

ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRWOMAN



PHAR. PHAM THI BICH THUY

No.: 03/TT-AGP.DHDCD

An Giang, February 14, 2025

PROPOSAL

SALARY AND BONUS FOR THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS

To: The 2025 Annual General Meeting of Shareholders

- Pursuant to the Enterprises Law No. 59/2020/QH14 on June 17, 2020, effective from January 1, 2021.
- Pursuant to the Charter of Organization and Operation of Agimexpharm Pharmaceutical Joint Stock Company.
- Pursuant to the Company's actual circumstances.

The Board of Directors respectfully submits to the 2025 General Meeting of Shareholders for approval:

1. Salary and bonus for the Board of Directors and the Board of Supervisors in 2024:

- | | |
|--|-----------------|
| - Salary paid in 2024: | VND 700,000,000 |
| - Bonus balance at the beginning of 2024: | VND 29,823,100 |
| - Bonus allocated from 2023 profit: | VND 551,745,246 |
| - Bonus paid in 2024: | VND 579,000,000 |
| - Remaining bonus carried forward to 2025: | VND 2,568,346 |

2. Salary and bonus plan for the Board of Directors and the Board of Supervisors in 2025:

- | | |
|---|---------------------------|
| - Fixed salary: | VND 700,000,000 per year |
| - Bonus for 2025 includes: | |
| + Meeting the profit before tax plan: | 1% of profit before tax |
| + Exceeding the profit before tax plan: | 5% of excess profit |
| + Bonus for the General Director for meeting the profit plan: | 0.5% of profit before tax |

We look forward to the approval of the Esteemed Shareholders.

Sincerely.

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRWOMAN
CÔNG TY
CP
DUỘC PHẨM
AGIMEXPHARM
T.P. LONG XUYẾN - T. AN GIANG



PHAR. PHAM THI BICH THUY

PROPOSAL

Re: Plan for issuing shares to pay 2024 dividends

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC

- Pursuant to the Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 dated on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP of the Government dated December 31, 2020, detailing the implementation of certain provisions of the Securities Law;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company (“the Company”).

The Board of Directors (“BoDs”) of Agimexpharm Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders (“GMS”) to approve a plan for issuing shares to pay 2024 dividend with the following contents:

1. **Name of share:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. **Share type:** Common shares
3. **Par value:** VND 10,000/share
4. **Current charter capital:** VND 231,439,410,000
5. **Total number of issued shares:** 23,143,941 shares
Of which:
 - Total number of outstanding shares: 23,143,941 shares
 - Total number of treasury shares: 0 shares
6. **Estimated number of shares to be issued:** 2,314,394 shares
7. **Total value of issuance at par value:** VND 23,143,940,000
8. **Eligible subscriber:** Existing shareholders whose names appear on the final shareholder list as of the record date. The record date for the shareholder list will be determined by the BoDs, as authorized by the GMS.
9. **Issuance ratio** (estimated number of shares to be issued/number of outstanding shares): 10%
10. **Subscription ratio:** 10:01. For every 1 share owned, a shareholder will receive 1 right to subscribe for additional shares. Every 10 rights will entitle the shareholder to 1 additional new share.
11. **Source of capital:** Retained earnings after tax as of December 31, 2024, based on the audited financial statements for the year 2024 of Agimexpharm Pharmaceutical Joint Stock Company.
12. **Issuance method:** The shares issued to existing shareholders will be distributed through the exercise of subscription rights.
13. **The plan to handle the fractional shares:** The number of additional shares issued to each shareholder will be rounded down to the nearest whole number, and any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 128 shares as of the record date. With a subscription ratio of 10:1, Shareholder A is entitled to receive $(128/10 * 1) = 12.80$ new shares. Following this calculation method, Shareholder A will receive 12 additional shares, and the fractional portion of 0.80 shares will be canceled.*

The difference between the total projected amount for issuing shares to pay dividends (calculated at a par value of VND 10,000 per share) and the total value of shares actually distributed to existing shareholders (calculated at a par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

14. Expected time of issuance: After the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2025. The GMS authorizes the BoDs to determine the appropriate issuance time to ensure shareholders' interests and compliance with legal regulations.

15. Additional securities registration and additional trading registration: The GMS approves and authorizes the BoDs to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.

16. Approval of charter capital amendment: Approve the amendment of the Company's Charter (regarding charter capital) and the adjustment of the Enterprise Registration Certificate with the Department of Planning and Investment of An Giang Province, following the written notification from the SSC confirming receipt of the issuance result report.

17. Authorization to the BoDs:

The GMS authorizes the Company's BoDs to carry out the following tasks related to the issuance:

- Make, amend, supplement, and finalize the content of the above-mentioned share issuance plan, and adjust the issuance plan along with other related documents as necessary, based on the actual situation of the Company, or as required by the SSC and other competent authorities, or to ensure compliance with relevant legal regulations (if any);
- Select the shareholder record date to implement the aforementioned share issuance plan;
- Make amendments and supplements to the relevant provisions in the Company's Charter to reflect the increased charter capital after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch, and additional trading registration with the Hanoi Stock Exchange for the number of additional shares issued, based on the actual results of the issuance, after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for amending the Company's business registration to reflect the change in charter capital based on the actual results of the issuance with competent authorities after the SSC provides written notification of the receipt of the issuance result report;
- Depending on specific circumstances, the BoDs may authorize the General Director to carry out one or several specific tasks mentioned above;
- Make decisions on any other issues arising related to the issuance of shares for dividend payment.

Respectfully submitted to the GMS for consideration and approval.


Sincerely thank you.

Recipients:

- Shareholders of the Company;
- Board of Directors;
- Archived: Secretary of the BoDs

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRWOMAN



PHẠM THỊ BÍCH THUY

PROPOSAL

Re: Plan for issuing shares under the Employee Stock Ownership Program (ESOP)

To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC

- Pursuant to the Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 dated on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP of the Government dated December 31, 2020, detailing the implementation of certain provisions of the Securities Law;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company ("the Company").

To implement the compensation policy, to encourage employees who have contributed to the development of the Company, and to supplement the Company's working capital, the Board of Directors ("BoDs") of Agimexpharm Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders ("GMS") for approval the share issuance plan under the Employee Stock Ownership Program ("ESOP") with the following details:

1. **Name of share:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. **Share type:** Common shares
3. **Securities code:** AGP
4. **Par value:** VND 10,000/share
5. **Current charter capital:** VND 231,439,410,000
6. **Total number of issued shares:** 23,143,941 shares
Of which:
 - Total number of outstanding shares: 23,143,941 shares
 - Total number of treasury shares: 0 shares
7. **Maximum number of shares expected to be issued:** 1,157,197 shares
8. **Maximum total value of issuance at par value:** VND 11,571,970,000
9. **Purpose of issuance:** To issue shares under the ESOP.
10. **Eligible subscriber:** Employees who have contributed to the development of Agimexpharm Pharmaceutical Joint Stock Company. The GMS authorizes the BoDs to approve the criteria, the list of employees eligible to participate in the program and the specific number of shares each employee is entitled to purchase.
11. **Issuance ratio (estimated number of shares to be issued/number of outstanding shares):**
5%

12. **Issuance price:** VND 18,000 per share
13. **Expected total funds to be raised:** VND 20,829,546,000
14. **Principles for determining the number of shares allocated to each employee:** The GMS authorizes the BoDs to decide the principles for determining the number of shares to be allocated to each employee at the time of issuance.
15. **Transfer restrictions:** Shares issued under the ESOP will be subject to a transfer restriction for 01 year from the end of the issuance period.
16. **Plan for handling when employees resign during the transfer restriction period:** The GMS has decided not to revoke the shares if employees resign during the transfer restriction period.
17. **Expected time of issuance:** After being approved by the GMS and the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2025. The GMS authorizes the BoDs to determine the appropriate issuance time to ensure shareholders' interests and compliance with legal regulations.
18. **Plan for using funds from the issuance:** The entire amount raised from the issuance will be used to supplement the working capital for the Company's business operations.
19. **Plan for handling unsubscribed shares:** The number of unsubscribed shares will be distributed to other eligible employees as authorized by the GMS in accordance with the program's purpose, provided that the offering price is not lower than VND 18,000 per share. In the event that the BoDs is unable to find suitable employees, the GMS authorizes the Board to adjust the total number of shares to be issued to reflect the actual number of shares distributed.
20. **Additional securities registration and additional trading registration:** The GMS approves and authorizes the BoDs to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.
21. **Approval of charter capital amendment:** Approve the amendment of the Company's Charter (regarding charter capital) and the adjustment of the Enterprise Registration Certificate with the Department of Planning and Investment of An Giang Province, following the written notification from the SSC confirming receipt of the issuance result report.

22. Authorization to the BoDs:

The GMS authorizes the Company's BoDs to carry out the following tasks related to the issuance:

- Make, amend, supplement, and finalize the content of the above-mentioned share issuance plan, and adjust the issuance plan along with other related documents as necessary, based on the actual situation of the Company, or as required by the SSC and other competent authorities, or to ensure compliance with relevant legal regulations (if any);
- Approve the plan to ensure that the share issuance complies with regulations on foreign ownership ratios in the event that shares are issued to foreign investors under the ESOP;
- Make a detailed working capital utilization plan;
- Decide the issuance timeline after the SSC confirms receipt of the complete issuance report from the Company;
- Approve the criteria and list of employees eligible to participate in the program, the principles for determining the number of shares allocated to each individual, and the implementation timeline;;

- Decide on the handling of unsubscribed shares (if any);
- Make amendments and supplements to the relevant provisions in the Company's Charter to reflect the increased charter capital after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange for the number of additional shares issued under the plan approved by the GMS, after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for amending the Company's business registration to reflect the change in charter capital based on the actual results of the issuance with competent authorities after the SSC provides written notification of the receipt of the issuance result report;
- Depending on specific circumstances, the BoDs may authorize the General Director to carry out one or several specific tasks mentioned above;
- Make decisions on any other issues arising related to the issuance of shares under ESOP.

Respectfully submitted to the GMS for consideration and approval.

Sincerely thank you.

Recipients:

- Shareholders of the Company;
- Board of Directors;
- Archived: Secretary of the BoDs .

ON BEHALF OF THE BOARD OF DIRECTORS



CHAIRWOMAN

PHẠM THỊ BÍCH THUY

No.: 06/TT-AGP.DHDCD

An Giang, February 14, 2025

PROPOSAL

**Regarding the Amendment of the Charter
of Agimexpharm Pharmaceutical Joint Stock Company**

- Pursuant to the Enterprises Law No. 59/2020/QH14 dated June 17, 2020;
- Pursuant to the Securities Law No. 54/2019/QH14 dated on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP of the Government dated December 31, 2020, detailing the implementation of certain provisions of the Securities Law;
- Pursuant to Circular No. 116/2020/TT-BTC of the Minister of Finance dated December 31, 2020, providing guidance on corporate governance regulations applicable to public companies;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company;
- Pursuant to current regulations and the practical needs of Agimexpharm Pharmaceutical Joint Stock Company.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the amendments to the Charter on organization and operation of Agimexpharm Pharmaceutical Joint Stock Company as follows:

Charter (May 2024)	Amended content 2025	Notes
Introduction	Introduction	
This Charter was approved by the 2024 Annual General Meeting of Shareholders on March 15, 2024, and was amended and supplemented according to the Board of Directors' Resolution No. 06/NQ-AGP.HDQT dated May 20, 2024. The company is organized and operates in accordance with this Charter, the Law on Enterprises, and other relevant current legal regulations.	This Charter was approved by the 2025 Annual General Meeting of Shareholders on March 8, 2025, and was amended and supplemented according to the Board of Directors' Resolution No. .../NQ-AGP.HDQT dated, 2025. The company is organized and operates in accordance with this Charter, the Law on Enterprises, and other relevant current legal regulations.	Amended in accordance with the approval at the 2025 Annual General Meeting of Shareholders and any Board of Directors' Resolutions (if any).
Article 5. Charter capital, shares and founding shareholders	Article 5. Charter capital, shares and founding shareholders	
1. The Company's charter capital is VND 231,439,410,000 (<i>two hundred thirty-one billion, four hundred thirty-nine million, four hundred ten thousand Vietnamese dong</i>).	1. The Company's charter capital is VND (<i>.....</i>). The total charter capital is divided into shares , with a par value of VND 10,000 per share .	Amended based on the actual results of the issuance of shares for dividend payment and the issuance of shares under the

Charter (May 2024)	Amended content 2025	Notes
The total charter capital is divided into 23,143,941 shares , with a par value of VND 10,000 per share .		employee stock option program (ESOP)
Article 53. Effective date	Article 53. Effective date	
1. This Charter, consisting of 21 chapters with 53 articles, was approved by the 2024 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company on March 15, 2024 in An Giang and amended and supplemented on May 20, 2024, as per the Resolution No. 06/NQ-AGP.HĐQT of the Board of Directors. The full text of this Charter takes effect as of May 20, 2024.	1. This Charter, consisting of 21 chapters with 53 articles, was approved by the 2025 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company on March 08, 2025 in An Giang and amended and supplemented on, 2025, as per the Resolution No. .../NQ-AGP.HĐQT of the Board of Directors. The full text of this Charter takes effect as of, 2025.	Amended in accordance with the approval at the 2025 Annual General Meeting of Shareholders and any Board of Directors' Resolutions (if any).

The General Meeting of Shareholders authorizes the Board of Directors to amend the Company's Charter and carry out the necessary procedures in accordance with applicable laws.

Sincerely.

Recipients:

- Shareholders of the Company;
- Board of Directors, Board of Supervisors, Board of Management
- Archived: Secretary of the BoDs

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRWOMAN



PHẠM THỊ BÍCH THUY